XENOTHERA

Description

XENOTHERA develops glyco humanized antibody technology for immunological treatments, lists pipeline products and clinical trials for eligible volunteer patients, and advances XON11 as an antibody aimed at pancreatic cancer.

Related

• BioInvent InternationalBioInvent International discovers and develops antibody therapeutics for cancer treatment, using immunology, cancer biology, antibody…
• Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
• Rab DiagnosticsRab Diagnostics develops biomarker tools, assays and the RabCANCER platform to predict antibody–drug conjugate response for pharma…
• Numab TherapeuticsNumab Therapeutics engineers multispecific antibodies, combining antibody engineering and Swiss scientific expertise to build a proprietary…
• Ability PharmaceuticalsAbility Pharmaceuticals develops oral targeted anticancer compounds that induce selective autophagy-mediated cytotoxicity in cancer cells;…
• RRiviaRivia provides a unified intelligence layer that ingests and harmonizes fragmented clinical trial data, applies structured trial models,…
• CiMaasCiMaas develops immunotherapy products that expand and engineer natural killer (NK) cells for adoptive cell therapy and CAR‑NK applications…
• Orakl OncologyOrakl Oncology builds an AIxBio engine that analyzes multimodal patient data and living biological samples to predict drug responses,…
• SciRhomSciRhom develops humanized antibodies against iRhom2 that selectively inhibit TACE in immune cells, blocking TNF-alpha, IL-6, and HB-EGF…